HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model.

Abstract
The cytoskeletal and neuronal protective effects of early treatment with the blood-brain barrier- and cell-permeable calpain inhibitor MDL-28170 was examined in the controlled cortical impact (CCI) traumatic brain injury (TBI) model in male CF-1 mice. This was preceded by a dose-response and pharmacodynamic evaluation of IV or IP doses of MDL-28170 with regard to ex vivo inhibition of calpain 2 activity in harvested brain homogenates. From these data, we tested the effects of an optimized MDL-28170 dosing regimen on calpain-mediated degradation of the neuronal cytoskeletal protein α-spectrin in cortical or hippocampal tissue of mice 24 h after CCI-TBI (1.0 mm depth, 3.5 m/sec velocity). With treatment initiated at 15 min post-TBI, α-spectrin degradation was significantly reduced by 40% in hippocampus and 44% in cortex. This effect was still observed with a 1-h but not a 3-h post-TBI delay. The cytoskeletal protection is most likely taking place in neurons surrounding the area of mainly necrotic degeneration, since MDL-28170 did not reduce hemispheric lesion volume as measured by the aminocupric silver staining method. This lack of effect on lesion volume has been seen with other calpain inhibitors, which suggests that pharmacological calpain inhibition by itself, while able to reduce axonal injury, may not be able to produce a measurable reduction in lesion volume. This is in contrast to certain other neuroprotective mechanistic approaches such as the mitochondrial protectant cyclosporine A, which produces at least a partial decrease in lesion volume in the same model. Accordingly, the combination of a calpain inhibitor with a compound such as cyclosporine A may be needed to achieve the optimal degree of post-TBI neuroprotection.
AuthorsStephanie N Thompson, Kimberly M Carrico, Ayman G Mustafa, Mona Bains, Edward D Hall
JournalJournal of neurotrauma (J Neurotrauma) Vol. 27 Issue 12 Pg. 2233-43 (Dec 2010) ISSN: 1557-9042 [Electronic] United States
PMID20874056 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Dipeptides
  • Spectrin
  • Calpain
  • calpain inhibitor III
Topics
  • Analysis of Variance
  • Animals
  • Blood-Brain Barrier (drug effects, metabolism, pathology)
  • Blotting, Western
  • Brain Injuries (drug therapy, pathology)
  • Calpain (antagonists & inhibitors)
  • Cerebral Cortex (drug effects, injuries, metabolism, pathology)
  • Dipeptides (pharmacology, therapeutic use)
  • Dose-Response Relationship, Drug
  • Hippocampus (drug effects, metabolism, pathology)
  • Male
  • Mice
  • Nerve Degeneration (drug therapy, metabolism, pathology)
  • Neurons (drug effects, metabolism, pathology)
  • Spectrin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: